RxSight, Inc. (RXST) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. RxSight, Inc. is a commercial-stage medical technology company focused on the RxSight Light Adjustable Lens (LAL) system, a premium cataract technology that allows doctors to customize visual acuity post-surgery. The company operates in a single reportable segment and is headquartered in Aliso Viejo, California.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Sales | $30.9 million | $37.9 million |
| Gross Profit | $23.5 million | $28.3 million |
| Gross Margin | 76.1% | 74.8% |
| Operating Loss | $(17.8) million | $(10.7) million |
| Net Loss | $(15.9) million | $(8.2) million |
| Net Loss Per Share (Basic & Diluted) | $(0.38) | $(0.20) |
| Cash, Cash Equivalents & Short-Term Investments | $217.9 million | $228.1 million (Dec 31, 2025) |
| Accumulated Deficit | $(676.9) million | $(661.0) million (Dec 31, 2025) |
| Operating Cash Flow | $(10.9) million | $(8.8) million |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased by 18.5% ($7.0 million) year-over-year. The decline was primarily driven by lower volumes of Light Delivery Device (LDD) sales ($2.4 million vs. $9.4 million in Q1 2025), while LAL sales remained relatively flat ($27.0 million vs. $27.2 million).
- Increased Operating Loss: The operating loss widened by 67.0% to $17.8 million. This was due to the revenue decline combined with an 11.2% increase in Selling, General, and Administrative (SG&A) expenses to $31.9 million, driven by personnel-related expenses and commercial expansion.
- Improved Gross Margin: Despite lower revenue, gross margin improved to 76.1% from 74.8%, attributed to a favorable product mix with a higher percentage of revenue coming from high-margin LAL sales.
- Inventory Build: Net cash used in operating activities increased, partly due to a $3.4 million increase in inventory levels.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($217.9 million) are sufficient to fund operations for at least the next 12 months. The company does not anticipate the immediate need to raise additional capital but may do so opportunistically.
- Commercial Strategy: The company recently realigned its U.S. commercial organization, integrating clinical and sales teams into a "Customer Success Organization" to drive utilization growth. They expect to continue incurring net operating losses in the near future as they invest in sales, marketing, and R&D.
- Legal Proceedings: The company is facing a consolidated securities class action lawsuit (In re RxSight Securities Litigation) alleging false statements regarding product demand and financial guidance. A hearing on the motion to dismiss is scheduled for May 28, 2026. Related shareholder derivative actions are currently stayed pending the resolution of the class action.
- Risk Factors: Key risks include supply chain constraints (reliance on single/sole source suppliers), potential tariffs, the need for continued regulatory compliance (FDA QMSR), and the volatility of the medical device market.
Investor Verification Checklist
- Revenue Mix Sustainability: Verify if the shift toward LAL sales (higher margin) can offset the decline in LDD capital equipment sales to stabilize total revenue.
- Commercial Realignment Impact: Monitor future quarters to see if the new "Customer Success Organization" structure successfully drives LAL utilization rates and revenue growth.
- Legal Exposure: Track the outcome of the motion to dismiss in the securities class action litigation, as an adverse ruling could result in significant costs and reputational damage.
- Supply Chain Resilience: Assess the company's ability to manage inventory levels and mitigate risks associated with single-source suppliers and potential tariff increases.
- Cash Burn Rate: Confirm that the current cash runway of ~12 months remains accurate given the increased operating losses and inventory build-up.